Evoke Pharma (NASDAQ:EVOK) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Evoke Pharma (NASDAQ:EVOK) to a hold rating in a research note released on Saturday morning.

A number of other analysts also recently issued reports on EVOK. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Evoke Pharma in a research report on Monday, December 15th. Laidlaw downgraded Evoke Pharma from a “buy” rating to a “hold” rating in a research note on Thursday, November 6th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Evoke Pharma has a consensus rating of “Reduce”.

Evoke Pharma Stock Up 0.4%

NASDAQ EVOK opened at $11.00 on Friday. The firm’s 50 day moving average is $8.89 and its 200-day moving average is $6.03. The company has a market capitalization of $18.92 million, a PE ratio of -5.31 and a beta of -0.15. Evoke Pharma has a 12-month low of $1.94 and a 12-month high of $11.00.

Evoke Pharma (NASDAQ:EVOK) last released its earnings results on Thursday, November 13th. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.45). Evoke Pharma had a negative net margin of 36.23% and a negative return on equity of 101.40%. The business had revenue of $4.28 million during the quarter, compared to the consensus estimate of $4.33 million.

Insider Buying and Selling

In other Evoke Pharma news, major shareholder Roger M. Klein sold 9,000 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $10.65, for a total transaction of $95,850.00. Following the transaction, the insider owned 29,000 shares of the company’s stock, valued at $308,850. The trade was a 23.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 2.29% of the company’s stock.

Institutional Trading of Evoke Pharma

An institutional investor recently bought a new position in Evoke Pharma stock. National Wealth Management Group LLC purchased a new stake in Evoke Pharma, Inc. (NASDAQ:EVOK) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 80,130 shares of the specialty pharmaceutical company’s stock, valued at approximately $398,000. National Wealth Management Group LLC owned 5.14% of Evoke Pharma as of its most recent SEC filing.

About Evoke Pharma

Evoke Pharma, Inc is a clinical-stage specialty pharmaceutical company focused on developing novel therapies for gastrointestinal (GI) motility disorders. The company’s lead product candidate, relamorelin, is a selective ghrelin receptor agonist designed to restore gastric motility and accelerate gastric emptying in conditions such as diabetic gastroparesis. Relamorelin has been granted orphan drug designation by the U.S. Food and Drug Administration and has demonstrated proof-of-concept activity in multiple clinical trials, positioning it as a promising treatment for patients with impaired GI function.

In addition to relamorelin, Evoke Pharma is advancing earlier-stage programs targeting metabolic and GI conditions, leveraging its expertise in peptide chemistry and receptor pharmacology.